Semaglutide for Heart Failure (HFpEF): What STEP-HFpEF Actually Showed

Heart failure with preserved ejection fraction (HFpEF) is one of the hardest forms of heart failure to treat, and for decades almost nothing helped patients feel better. The STEP-HFpEF program tested whether semaglutide 2.4 mg, the same drug sold as Wegovy for weight loss, could change that for people whose heart failure is tangled up with obesity. This article walks through what those trials actually measured, what the numbers showed, and where the evidence is strong versus where it is still thin.

What HFpEF Is and Why It's Hard to Treat

Heart failure comes in two broad flavors. In one, the heart's main pumping chamber is weak and can't squeeze out enough blood. Doctors call that heart failure with reduced ejection fraction. In the other, the heart squeezes fine but the muscle is stiff and doesn't relax and fill properly between beats. That's heart failure with preserved ejection fraction, or HFpEF.

"Ejection fraction" is the share of blood pumped out with each beat. A normal value is roughly 50% to 70%. In HFpEF, ejection fraction is preserved (45% or higher in these trials) but people still get short of breath, retain fluid, and tire quickly with activity.

HFpEF is now about half of all heart failure cases, and it's climbing. It tracks closely with aging, high blood pressure, diabetes, and obesity. For a long time, the drugs that rescued patients with the weak-pump type did little or nothing for HFpEF. That left a large group of people with real symptoms and few proven options. A specific slice of these patients carry a lot of extra weight, and in them, obesity isn't just a bystander. Fat tissue drives inflammation, fluid overload, and the mechanical strain that makes HFpEF worse. That insight is what set up the semaglutide trials.

The Idea Behind Testing Semaglutide in HFpEF

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that lowers appetite and slows stomach emptying, which leads to substantial weight loss. It also lowers inflammation and improves how the body handles blood sugar and blood pressure.

The hypothesis was simple. If obesity is a major engine of obesity-related HFpEF, then losing a large amount of weight should ease the disease, not just the number on the scale. Less fat could mean less inflammation, less fluid retention, a lower workload on a stiff heart, and better exercise tolerance.

That's a mechanism worth testing, but a mechanism is not proof. Plenty of plausible heart failure ideas have failed in trials. So Novo Nordisk ran a dedicated, randomized, placebo-controlled program built specifically around the symptom and function questions that matter most to HFpEF patients.

There's a deeper biological logic worth spelling out, because it's why HFpEF, and not the weak-pump type, was the target. In obesity-related HFpEF, excess fat, especially the fat packed around and inside the heart and in the belly, isn't inert storage. It releases inflammatory signals, holds onto sodium and water, and physically crowds the heart inside the chest. A stiff left ventricle that already struggles to fill is squeezed further by this surrounding pressure. The result is the classic HFpEF picture: pressures rise inside the heart during even mild exertion, the lungs get congested, and the person has to stop and catch their breath. Stripping away a large share of that fat, the theory goes, should relieve several of these problems at once rather than just one. That's a different bet than simply lowering blood pressure or removing fluid, and it's why a weight-loss-grade drug was a reasonable candidate here.

The STEP-HFpEF Trials at a Glance

The program had two sibling trials that were nearly identical in design, run so their results could be pooled.

• STEP-HFpEF enrolled 529 people who had obesity-related HFpEF but did not have type 2 diabetes.
• STEP-HFpEF DM enrolled 616 people who had obesity-related HFpEF and type 2 diabetes.

Both randomly assigned participants to once-weekly semaglutide 2.4 mg or a matching placebo for 52 weeks. To get in, people needed an ejection fraction of at least 45%, a body mass index of 30 or higher, New York Heart Association class II to IV symptoms, and a baseline quality-of-life score that left room to improve.

Both trials used two co-primary endpoints chosen on purpose: the change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), and the change in body weight. KCCQ-CSS runs from 0 to 100, with higher scores meaning fewer symptoms and physical limitations. A change of about 5 points is generally considered clinically meaningful to patients. This is important to understand up front: the trials were designed to test how people feel and function, plus weight, not primarily to test whether semaglutide prevents deaths or hospitalizations.

The Headline Numbers

The two trials, and their pooled analysis, told a consistent story. Below are the verified primary and key secondary results.

Endpoint (52 weeks)	STEP-HFpEF (no diabetes)	STEP-HFpEF DM (diabetes)	Pooled (1,145 patients)
KCCQ-CSS difference vs placebo	+7.8 points (95% CI 4.8 to 10.9)	+7.3 points (95% CI 4.1 to 10.4)	+7.5 points (95% CI 5.3 to 9.8)
Body weight difference vs placebo	-10.7 percentage points	-6.4 percentage points	-8.4%
6-minute walk distance difference	+20.3 m (95% CI 8.6 to 32.1)	+14.3 m (95% CI 3.7 to 24.9)	+17.1 m (95% CI 9.2 to 25.0)
Hierarchical composite win ratio	1.72 (95% CI 1.37 to 2.15)	1.58 (95% CI 1.29 to 1.94)	1.65 (95% CI 1.42 to 1.91)
C-reactive protein (inflammation)	-43.5% vs -7.3%	treatment ratio 0.67	treatment ratio 0.64

Every comparison favored semaglutide, and almost all were highly statistically significant. The KCCQ improvement of roughly 7 to 8 points is larger than the 5-point threshold patients typically notice, and it's a bigger symptom gain than most HFpEF drugs have ever delivered. People walked farther on a 6-minute test. Inflammation, measured by C-reactive protein, dropped sharply. And the weight loss was substantial.

The "hierarchical composite" deserves a plain-English note. It's a win-ratio method that stacks the most serious events first (death, then heart failure events) before comparing symptom and walk-distance changes. A win ratio above 1 means semaglutide patients "won" more head-to-head comparisons than placebo patients. The 1.65 pooled figure is solid, but most of those wins came from symptom and function differences, not from a large gap in hard events.

A couple of details make these results more convincing, not less. First, the placebo groups didn't sit still: their KCCQ scores rose by roughly 6 to 9 points on their own, which is normal in trials where everyone gets closer attention to their care. The semaglutide benefit is the gap on top of that placebo improvement, so the real-world effect is the 7-to-8-point difference, not the raw 16-point rise in the semaglutide arm. Second, the effect held up across the prespecified subgroups the investigators examined, including different ages, baseline symptom severity, and ejection-fraction ranges within the preserved band. When a benefit shows up consistently rather than only in one lucky slice of patients, it's more believable. Third, the inflammation drop measured by C-reactive protein wasn't a side note; it lined up with the weight loss and supports the idea that easing obesity's inflammatory load is part of how the drug works here.

One more nuance: the symptom and weight benefits were only partly linked. Statistical analyses from the program suggested that some of the KCCQ improvement traveled with the amount of weight lost, but not all of it. In other words, weight loss explains a chunk of why people felt better, yet there appears to be more going on, possibly the anti-inflammatory and fluid effects, than weight alone. That's a useful clue about mechanism, but it shouldn't be read as a precise, proven breakdown.

Honest Grading: What the Evidence Does and Doesn't Show

This is where it pays to be careful, because the marketing temptation is to call semaglutide a "heart failure drug" full stop. The data support something narrower.

Strong evidence (graded high): In adults with obesity-related HFpEF and an ejection fraction of 45% or higher, semaglutide 2.4 mg over a year produces meaningful, reproducible improvements in heart-failure symptoms, physical limitations, exercise capacity, weight, and inflammation. Two separate randomized trials plus a pooled analysis of over 1,100 patients agree. That's about as good as symptom evidence gets in HFpEF.

Weaker evidence (graded low to moderate): Whether semaglutide reduces hard outcomes, meaning death or heart failure hospitalizations, is not established by these trials. They weren't sized or designed to prove it. Deaths and heart failure events were uncommon and counted as part of the composite, not as a stand-alone, adequately powered endpoint. The trials also ran only 52 weeks. Encouraging? Yes. Proven? No. Anyone telling you semaglutide is shown to prevent heart failure deaths in HFpEF is reaching past the data.

It's worth separating this from the broader cardiovascular story. In the large SELECT trial of people with obesity and established cardiovascular disease (but no diabetes), semaglutide did cut major cardiovascular events like heart attack and stroke. But SELECT was not a HFpEF symptom trial, and you shouldn't blur the two. The HFpEF win is about feeling and functioning better; the SELECT win is about cardiovascular events in a different population.

How Semaglutide Compares to Other HFpEF Options

For years the HFpEF cupboard was nearly bare. That's changed.

Option	What it's shown in HFpEF	Strength of evidence
SGLT2 inhibitors (empagliflozin, dapagliflozin)	Reduce heart failure hospitalizations across the ejection-fraction spectrum; modest symptom gains	Strong for hospitalizations; guideline-recommended
Semaglutide 2.4 mg	Large symptom, function, weight, and inflammation gains in obesity-related HFpEF	Strong for symptoms/function; not proven for hard outcomes
Tirzepatide (SUMMIT trial)	Lowered a composite of cardiovascular death or worsening heart failure, plus symptom gains	Promising; one trial
Loop diuretics (furosemide, etc.)	Relieve fluid overload and congestion symptoms	Standard supportive care, not disease-modifying
Blood pressure and rate control	Manage drivers like hypertension and atrial fibrillation	Foundational background care

The newest and most interesting comparison is tirzepatide, the dual GIP/GLP-1 drug in Mounjaro and Zepbound. The SUMMIT trial randomized 731 patients with HFpEF and obesity to tirzepatide or placebo. It reported a lower risk of its composite of cardiovascular death or worsening heart failure (hazard ratio 0.62, 95% CI 0.41 to 0.95) along with a KCCQ-CSS improvement of about 6.9 points versus placebo. That's notable because SUMMIT's primary endpoint included an event component, edging closer to the hard-outcome question that STEP-HFpEF wasn't built to answer. Still, it's a single trial, and the cardiovascular death numbers were small in both arms, so the event signal needs confirmation.

The practical takeaway: SGLT2 inhibitors and these incretin drugs aren't really rivals. Many patients with obesity-related HFpEF are candidates for an SGLT2 inhibitor and a GLP-1-based drug, addressing different parts of the problem. The SGLT2 inhibitors have the thing semaglutide lacks here: large outcome trials showing fewer heart-failure hospitalizations across the ejection-fraction spectrum, which is why guidelines already recommend them. Semaglutide brings the larger symptom and weight effect in the specific obesity-related group. Pairing them targets congestion and hard-outcome risk on one side and the obesity-inflammation engine on the other.

It's also worth being clear about what semaglutide is not competing against. Loop diuretics still do the day-to-day work of pulling off fluid when someone is congested; nothing here replaces them. Blood pressure control, rate control for atrial fibrillation, and treating sleep apnea remain the background that any HFpEF plan is built on. Semaglutide is an addition to that foundation in the right patient, not a substitute for it. For more on how semaglutide and tirzepatide stack up overall, see our semaglutide vs tirzepatide head-to-head comparison.

Safety: What the Trials Reported

One of the more striking findings is that semaglutide patients had fewer serious adverse events than placebo patients. In STEP-HFpEF, serious adverse events hit 13.3% of the semaglutide group versus 26.7% of placebo. In STEP-HFpEF DM, it was 17.7% versus 28.8%. That's partly because untreated, symptomatic HFpEF generates its own hospitalizations and complications, and easing the disease cut those.

That said, the familiar GLP-1 side effects still showed up. The most common are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually worst during dose increases and easing over time. Some patients stopped the drug because of these effects.

A few HFpEF-specific cautions are worth flagging:

• Volume and diuretics. Weight loss and reduced fluid retention can change how much diuretic a patient needs. This is something to monitor with a clinician, not adjust alone.
• Lean mass. Big weight loss includes some muscle loss, which matters in older, deconditioned HFpEF patients. Protein intake and resistance exercise help protect muscle. See our guide on preventing muscle loss on GLP-1 medications.
• Class warnings. GLP-1 drugs carry the usual labeled cautions around pancreatitis, gallbladder disease, and a boxed warning regarding thyroid C-cell tumors seen in rodents. For the full picture, read our complete GLP-1 side effects guide.

Importantly, the trials did not surface a new heart-specific danger. The safety profile in HFpEF looked like the GLP-1 safety profile elsewhere.

A practical point on dose and timing: these trials used the full 2.4 mg weekly dose, reached through a gradual titration over several weeks. That slow ramp exists precisely to blunt the gastrointestinal effects, and it's why a patient's experience in the first month or two often looks rougher than their experience at six months. Stopping the drug early because of transient nausea can mean walking away before the heart-failure benefits, which were measured at a full year, have a chance to show up. For HFpEF patients specifically, the bigger watch item is the diuretic interaction. As fluid retention eases and weight comes off, the dose of furosemide or another loop diuretic that was right last month may be too much this month, raising the risk of dehydration, low blood pressure, or kidney strain. That's a manageable issue, but it's a reason this drug belongs in a monitored plan rather than a self-directed one.

Who This Evidence Actually Applies To

The trials drew a fairly specific box, and it's worth staying inside it when interpreting the results.

This evidence applies most directly to:

• Adults with HFpEF and an ejection fraction of at least 45%
• A body mass index of 30 or higher (obesity-related HFpEF)
• Meaningful symptoms (NYHA class II to IV) with room to improve on quality-of-life scores
• Both with and without type 2 diabetes, since both were studied

It does not directly speak to:

• People with HFpEF who are not obese, who weren't enrolled
• People with reduced ejection fraction (the weak-pump type), a different disease with its own trials
• Patients seeking proof that the drug will keep them out of the hospital or extend life, which these trials weren't built to show

If you carry obesity, have symptomatic HFpEF, and your daily life is limited by breathlessness and fatigue, this is the population that gained the most. The decision still belongs with a cardiologist who knows your full picture, including whether an SGLT2 inhibitor, a GLP-1-based drug, or both make sense, and how to handle cost and access. For the wider view of cardiovascular benefits, see our roundup of what the latest GLP-1 research shows on benefits and our look at GLP-1 use after a heart attack.

Cost and Access Reality

Semaglutide 2.4 mg (Wegovy) is FDA-approved for weight management and, more recently, to reduce cardiovascular risk in adults with established cardiovascular disease and obesity. As of mid-2026 there is no separate FDA indication specifically for "HFpEF." That matters for insurance: coverage often hinges on the approved use and on a person's weight or cardiovascular history, not on a HFpEF diagnosis by itself.

List prices remain high, often well over $1,000 a month before insurance or savings programs. Coverage is uneven and depends heavily on the plan and the indication. If cost is the main barrier, our GLP-1 medication cost guide for 2026 breaks down pricing, savings cards, and lower-cost paths. Don't let a HFpEF interest push you toward unverified compounded sources to save money without talking to your clinician first.

The Bottom Line

For the right patient, obese, symptomatic, with preserved ejection fraction, semaglutide 2.4 mg is one of the most convincing symptom-and-function wins HFpEF has ever seen, backed by two randomized trials and a pooled analysis. The honest caveat is just as important: it's proven to help people feel and move better and lose weight, not yet proven to prevent deaths or hospitalizations in this group, and the data run a year, not a decade. Used in the right person, alongside the rest of guideline care, it's a meaningful tool. Sold as a cure-all heart failure drug, it's oversold.

Frequently Asked Questions

Is semaglutide FDA-approved specifically for heart failure?

No. As of mid-2026, semaglutide 2.4 mg (Wegovy) is approved for chronic weight management and to reduce cardiovascular risk in adults with established cardiovascular disease and obesity. There is no stand-alone FDA indication for HFpEF. The STEP-HFpEF trials are strong clinical evidence, but they are not the same thing as a formal heart-failure approval, and coverage decisions usually follow the approved uses.

Did the STEP-HFpEF trials show semaglutide prevents deaths or hospitalizations?

Not in a way that's proven. The trials were designed around symptoms, physical function, and weight, not hard outcomes. Deaths and heart failure events were uncommon and folded into a composite endpoint rather than measured as an adequately powered, stand-alone result. The trends were encouraging, but anyone claiming semaglutide is shown to prevent HFpEF deaths is overstating the evidence.

How much did symptoms actually improve?

Across the program, the KCCQ-CSS quality-of-life score improved by roughly 7 to 8 points more with semaglutide than placebo over 52 weeks. Since about 5 points is the threshold patients typically notice, that's a clinically meaningful gain, and larger than most prior HFpEF treatments delivered. Patients also walked farther on a 6-minute walk test, about 17 meters more than placebo in the pooled analysis.

How does semaglutide compare to tirzepatide for HFpEF?

Both helped in obesity-related HFpEF. Semaglutide's STEP-HFpEF program proved large symptom, function, and weight benefits. Tirzepatide's SUMMIT trial went a step further on the outcome question, reporting a lower risk of a composite of cardiovascular death or worsening heart failure (hazard ratio 0.62). SUMMIT's event signal is promising but comes from a single trial with few events, so it needs confirmation. Neither has fully settled the long-term mortality question.

Can someone with HFpEF who isn't overweight expect the same benefit?

The trials don't tell us. Enrollment required a body mass index of 30 or higher, so the entire benefit was studied in obesity-related HFpEF. The leading theory is that much of the gain comes from reversing obesity's effects on the heart, which suggests the benefit may be smaller in lean HFpEF patients, but that's an inference, not a tested result. A cardiologist should weigh in for anyone outside the studied population.

---

This article is for general education and is not medical advice. Talk to a qualified clinician before starting, stopping, or changing any medication, especially if you have heart failure.

References

• STEP-HFpEF: Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (NEJM 2023)
• STEP-HFpEF DM: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes (NEJM 2024)
• Pooled analysis of STEP-HFpEF and STEP-HFpEF DM (The Lancet 2024)
• SUMMIT: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (NEJM 2025)
• SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (NEJM 2023)
• PubMed: semaglutide and HFpEF research
• FDA Drugs@FDA: Wegovy (semaglutide) approval history
• ClinicalTrials.gov: STEP-HFpEF (NCT04788511)